__NUXT_JSONP__("/drugs/Cobimetinib", (function(a,b,c,d){return {data:[{drug:{slug:a,emaEpar:[{activeSubstance:"cobimetinib hemifumarate",conditionIndication:"Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",inn:"cobimetinib",marketingAuthorisationDate:"2015-11-20 01:00:00",marketingAuthorisationHolder:"Roche Registration GmbH",medicineName:c,url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Fcotellic"}],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:b,chebiId:b,chemicalFormula:b,definition:"An orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity. Cobimetinib specifically binds to and inhibits the catalytic activity of MEK1, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation and activation and decreased tumor cell proliferation. Preclinical studies have demonstrated that this agent is effective in inhibiting the growth of tumor cells bearing a B-RAF mutation, which has been found to be associated with many tumor types. A threonine-tyrosine kinase and a key component of the RAS\u002FRAF\u002FMEK\u002FERK signaling pathway that is frequently activated in human tumors, MEK1 is required for the transmission of growth-promoting signals from numerous receptor tyrosine kinases.",fdaUniiCode:"ER29L26N1X",identifier:"C68923",preferredName:a,semanticType:"Pharmacologic Substance",subclassOf:["C129825","C69145"],synonyms:["COBIMETINIB",a,c,"GDC-0973","MEK Inhibitor GDC-0973","XL518"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FCobimetinib",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("Cobimetinib","","Cotellic","2021-10-30T13:43:20.933Z")));